RxDoctor Payments Data

Debora Argetsinger

Gerontology · Wyoming, MINPI 1376931717

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (50.7%), food and beverage and education — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Abbott at 55.8% of the total. 2025 is the largest year on record at $3,254, more than ten times the $42 reported in 2023. Among gerontology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,962in general payments, 2019–2025

Across 90 payments — averaging $66.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Sanofi$589
  • AbbVie$537
  • EMD Serono, Inc.$329
  • Biogen$150
  • TG Therapeutics, Inc.$122
  • plus $908 from 19 others

What the payments were for

  • Consulting fees$1503%
  • Travel & lodging$3,02351%
  • Food & beverage$2,58343%
  • Education$2073%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,962 in reported general payments places this provider in the 90th percentile of 279 gerontology providers in Michigan.

See all gerontology providers in Michigan

Medicare billing

Part B allowed, 2024
$16,000
Medicare patients
116
Services billed
260

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide13$19,329
NeuproRotigotine15$16,856
Carbidopa-LevodopaCarbidopa/Levodopa306$9,267
Carbidopa18$6,320
Primidone73$2,450
Carbidopa-Levodopa ErCarbidopa/Levodopa80$2,337
Omeprazole47$1,369
Propranolol Hcl ErPropranolol Hcl58$1,342
Atropine Sulfate12$1,018
Gabapentin73$939
Baclofen24$331
Pantoprazole Sodium18$277
Lacosamide12$270
Propranolol Hcl27$264
Memantine Hcl12$258

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$537$19,32913 claims
Upsher-smith Laboratories LLCTopiramate$33$15015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 279 gerontology providers in Michigan.

Other gerontology in Wyoming

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →